Prostate cancer is the most common malignancy and third leading cause of cancer-related mortality in American men. Due to the ageing """"""""baby boomers"""""""", the number of men with localized prostate cancer will increase, as will the need for an accurate non-invasive imaging tool. Magnetic Resonance (MR) imaging has the ability to deliver precise anatomical mapping of tumor. Newer MR techniques allow for pharmacokinetic (PK) evaluation of prostate tissue. This functional aspect of MR imaging could contribute greatly to the accuracy of tumor detection and localization, and potentially serve as a guide for focal ablative therapy, or non-invasively assess functional aspects of prostate tissue microcirculation in response to neoadjuvant treatment. The objective of this study is therefore to determine if optimized MR analysis tools and algorithms can be used as a biomarker guide for targeted therapy and as a surrogate for disease recurrence in prostate cancer. We plan to achieve our objective through 4 specific aims: 1. To develop and implement imaging methodology and analysis tools for automated, robust quantitative assessment of prostate tumor volumetry and assessment of the functional properties (vascularity and permeability) using quantitative multi-parametric MR imaging (mpMRI). 2. To clinically validate the prostate mpMRI quantitative analysis tools described in Aim 1. We will perform a multivariate analysis of the results of the analyses tools, and patient-specific parameter maps for tumor localization (a summary statistic display) will be obtained and correlated with pathology at prostatectomy. 3. To determine the clinical use of the analysis tools as a biomarker guide for targeted therapy and as a surrogate for disease recurrence in low-risk prostate cancer patients. We will obtain mpMRI maps, detailing the index lesion and its margins, and register them with focal ablative therapy treatment planning images. Follow up mpMRI maps will be registered the pre-treatment maps to detect changes, and will be correlated with PSA to determine the """"""""expected"""""""" treatment margin and untreated prostate mpMRI characteristics. 4. To determine the clinical use of the analysis tools in evaluating tumor response to treatment with neoadjuvant androgen deprivation therapy (ADT) in patients with high-risk prostate cancer. We will assess the changes in mpMRI maps after 12 weeks of ADT to determine if prostate tumor vascular permeability changes may be a suitable predictor of pathological response, by correlation with prostatectomy specimens.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01CA151261-02S1
Application #
8335645
Study Section
Special Emphasis Panel (ZCA1-SRLB-V (M1))
Program Officer
Nordstrom, Robert J
Project Start
2010-09-22
Project End
2015-07-31
Budget Start
2011-08-01
Budget End
2012-12-31
Support Year
2
Fiscal Year
2011
Total Cost
$89,964
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Hassanzadeh, Elmira; Alessandrino, Francesco; Olubiyi, Olutayo I et al. (2018) Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer. Abdom Radiol (NY) 43:1237-1244
Bane, Octavia; Hectors, Stefanie J; Wagner, Mathilde et al. (2018) Accuracy, repeatability, and interplatform reproducibility of T1 quantification methods used for DCE-MRI: Results from a multicenter phantom study. Magn Reson Med 79:2564-2575
Newitt, David C; Malyarenko, Dariya; Chenevert, Thomas L et al. (2018) Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network. J Med Imaging (Bellingham) 5:011003
Taghipour, Mehdi; Ziaei, Alireza; Alessandrino, Francesco et al. (2018) Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy. Abdom Radiol (NY) :
Peled, Sharon; Vangel, Mark; Kikinis, Ron et al. (2018) Selection of Fitting Model and Arterial Input Function for Repeatability in Dynamic Contrast-Enhanced Prostate MRI. Acad Radiol :
Alessandrino, Francesco; Taghipour, Mehdi; Hassanzadeh, Elmira et al. (2018) Predictive role of PI-RADSv2 and ADC parameters in differentiating Gleason pattern 3?+?4 and 4?+?3 prostate cancer. Abdom Radiol (NY) :
Langkilde, Fredrik; Kobus, Thiele; Fedorov, Andriy et al. (2018) Evaluation of fitting models for prostate tissue characterization using extended-range b-factor diffusion-weighted imaging. Magn Reson Med 79:2346-2358
Fedorov, Andriy; Schwier, Michael; Clunie, David et al. (2018) An annotated test-retest collection of prostate multiparametric MRI. Sci Data 5:180281
Glazer, Daniel I; Hassanzadeh, Elmira; Fedorov, Andriy et al. (2017) Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology. Abdom Radiol (NY) 42:918-925
Hassanzadeh, Elmira; Glazer, Daniel I; Dunne, Ruth M et al. (2017) Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review. Abdom Radiol (NY) 42:278-289

Showing the most recent 10 out of 39 publications